Knowledgebase

KCL Ww FIELDLAB (1)

In the University of Warwick and King’s College London, the FIELD-LAB of NRG has found its first international partners. The universities will be involved in a project on cisplatin to improve existing treatment and to find out why it might not be as effective in all patients. By joining FIELD-LAB, the universities hope to accelerate the process. “The beauty of FIELD-LAB lies in providing a form of open European collaboration, by offering all partners valuable information and knowledge” says Dr Imberti, University of Warwick.

University Of Warwick Vierkant (1)

In the University of Warwick and King’s College London, the FIELD-LAB of NRG has found its first international partners. Despite the significant barriers created by both the COVID-pandemic and Brexit, researchers and scientists on both sides of the Channel managed to get things started and hope to present exciting new findings in due time. Dr Cinzia Imberti, Sir Henry Wellcome Postdoctoral Fellow, University of Warwick, UK and Nora Klaassen, project manager R&D at Field-Lab, Petten, the Netherlands, shed some light on how this collaboration started and its hopes for the future.

Harry Hendrikse

The market for lutetium-177 is expected to grow significantly in the coming years. There are many products in the clinical pipeline that use lutetium-177 as radioactive substance, and we are seeing new, up-and-coming therapies. A promising agent is lutetium-177 PSMA, which acts on the prostate-specific membrane antigen and is used in the treatment of metastasised prostate cancer. In addition to prostate carcinomas, other cancers could be treated with the isotope lutetium-177 in the future. Prof. Hendrikse of Amsterdam UMC, VUmc location, foresees expanding possibilities for patient treatment despite some issues related to market availability.

Field LAB Lutetium 177

Medical isotope offers great perspective for the effective treatment of various cancer indications with limited side effects

Thumbnail Presentatie James Collection Item

During the Targeted Radiopharmaceuticals Summit, James Nagarajah gave a presentation. In his presentation he spoke about the challenges that can be faced during the development of a new radio pharmaceutical, and how these can be overcome by collaborating with suppliers, industry partners and medical institutes.

CISSPECT DESK LAB Proefstudie

For the past few months, pharmacist Jeske Hendriksen has been working as a PhD student in the Antoni van Leeuwenhoek hospital, where she is conducting research into radioactive cisplatin in the CISSPECT project. In this project, she is working alongside technical physician Else Aalbersberg, who has been at the Antoni van Leeuwenhoek for 8 years and involved in the CISSPECT project since the start.

Petten starts production xenon  3496 xs

Thanks to intensive collaboration between Curium and NRG, a complex project has been brought to a successful conclusion: the development and installation of a production process for the medical isotope Xenon-133.

Fieldlab Employe Development New Nuclear Medicines

FIELD-LAB is the incubator for new nuclear medicines. Together with partners FIELD-LAB develops new nuclear medicine for personalised treatment of cancer patients.

Konijnenberg Op Congres NRG

Despite many innovative developments in nuclear medicine, bringing the nuclear end product to the physician and thus the patient, remains a long-term and (therefore) often frustrating mission. Hopefully, this will not be the case any longer, according to physicist dr. Mark Konijnenberg of the department Radiology and Nuclear Medicine, Erasmus MC in Rotterdam.

Reactor

Every day, 30.000 patients benefit from medical isotopes from Petten. The NRG reactor, where the medical isotopes are irradiated, changed its fuel to low-enriched uranium in 2006.